Page 36 - Haematologica June

F. Autore et al.
chronic lymphocytic leukemia cells: evi- dence for a methylation-dependent regula- tion mechanism. Blood. 2013;122(19):3317- 3321.
60. Strati P, Parikh SA, Chaffee KG, et al. CD49d associates with nodal presentation and sub- sequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2017;178(1):99- 105.
61. Shanafelt TD, Hanson C, Dewald GW, et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lym- phocytic leukemia and is related to CD49d expression. J Clin Oncol. 2008;26(14):e5-e6.
62. Conrad DH, Ford JW, Sturgill JL, Gibb DR. CD23: an overlooked regulator of allergic disease. Curr Allergy Asthma Rep. 2007;7(5):331-337.
63. Barna G, Reiniger L, Tatrai P, Kopper L, Matolcsy A. The cutoff levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematol Oncol. 2008;26 (3):167-170.
64. Jurisic V, Colovic N, Kraguljac N, Atkinson HD, Colovic M. Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters. Med Oncol. 2008;25(3):315-322.
65. Fournier S, Yang LP, Delespesse G, Rubio M, Biron G, Sarfati M. The two CD23 isoforms display differential regulation in chronic lymphocytic leukaemia. Br J Haematol. 1995;89(2):373-379.
66. Kriston C, Bödör C, Szenthe K, et al. Low CD23 expression correlates with high CD38 expression and the presence of trisomy 12 in CLL. Hematol Oncol. 2017;35(1):58-63.
67. Burton J, Kay NE. Does IL-2 receptor expres- sion and secretion in chronic B-cell leukemia have a role in downregulation of the immune system? Leukemia. 1994;8(1):92-96.
68. Molica S, Levato D, Dell'Olio M, et al. Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients. Results of a multivariate survival analysis. Haematologica. 1997;82(2):148-151.
69. Lúcio PJ, Faria MT, Pinto AM, et al. Expression of adhesion molecules in chronic B-cell lymphoproliferative disorders. Haematologica. 1998;83(2):104-111.
70. Angelopoulou MK, Kontopidou FN, Pangalis GA. Adhesion molecules in B- chronic lymphoproliferative disorders. Semin Hematol. 1999;36(2):178-197.
71. Hjalmar V, Hast R, Kimby E. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course. Eur J Haematol. 2002;68(3):127-134.
72. Tefferi A, Bartholmai B, Witzig TE, et al. Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet. 1997;95(2):173-177.
73. Knauf WU, Knuutila S, Zeigmeister B, Thiel
E. Trisomy 12 in B-cell chronic lymphocytic leukemia: Correlation with advanced dis- ease, atypical morphology, high levels of sol- uble CD25, and with refractoriness to treat- ment. Leuk Lymphoma. 1995;19(3-4):289- 294.
74. Knauf WU, Langenmayer I, Ehlers B, et al. Serum levels of soluble CD23, but not solu- ble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1997;89(11): 4241-4242.
75. Darzentas N, Hadzidimitriou A, Murray F, et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereo- typed antigen receptors: molecular and com- putational evidence. Leukemia. 2010;24(1): 125-132.
76. Rosén A, Murray F, Evaldsson C, Rosenquist R. Antigens in chronic lymphocytic leukemia-implications for cell origin and leukemogenesis. Semin Cancer Biol. 2010;20(6):400-409.
77. Maura F, Cutrona G, Fabris S, et al. Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One. 2011;6(8):e24313.
78. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transfor- mation to Richter syndrome. Clin Cancer Res. 2009;15(13):4415-4422.
79. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lym- phocytic leukemia carry stereotyped recep- tors: pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-270.
80. Athanasiadou A, Stamatopoulos K, Gaitatzi M, Stavroyianni N, Fassas A, Anagnostopoulos A. Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG- switched stereotyped immunoglobulins. Haematologica. 2008;93(3):473-474.
81. Zenz T, Vollmer D, Trbusek M, et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia. 2010;24(12):2072- 2079.
82. González-Gascón y Marín I, Hernández- Sánchez M, Rodríguez-Vicente AE, et al. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematol Oncol. 2016;34(2):84-92.
83. Villamor N, Conde L, Martínez-Trillos A, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27(5):1100-1106.
84. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329-331.
85. Balatti V, Lerner S, Rizzotto L, et al. Trisomy 12 CLLs progress through NOTCH1 muta- tions. Leukemia. 2013;27(3):740-743.
86. Weissmann S, Roller A, Jeromin S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocyt- ic leukemia (CLL): a study on 852 patients. Leukemia. 2013;27(12):2393-2396.
87. Sportoletti P, Baldoni S, Cavalli L, et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol. 2010;151(4):404-406.
88. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational acti- vation. J Exp Med. 2011;208(7):1389-1401.
89. Puente XS, Pinyol M, Quesada V, et al. Whole genome sequencing identifies recur- rent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
90. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013;121(3):468-475.
91. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in +12 chronic lym- phocytic leukemia (CLL) confer an unfavor- able prognosis, induce a distinctive tran- scriptional profiling and refine the interme- diate prognosis of +12 CLL. Haematologica. 2012;97(3):437-441.
92. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119(2):521-529.
93. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391- 3401.
94. Yaktapour N, Übelhart R, Schüler J, et al. Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. Blood. 2013;122(9):1621-1633.
95. Maura F, Mosca L, Fabris S, et al. Insulin growth factor 1 receptor expression is asso- ciated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. PLoS One. 2015;10 (3):e0118801.
96. Medyouf H, Gusscott S, Wang H, et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med. 2011;208(9):1809-1822.
97. Mittal AK, Hegde GV, Aoun P, et al. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities. Int J Mol Med. 2007;20(4): 461-469.
98. Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lympho- cytic leukemia/small lymphocytic lym- phoma. J Clin Oncol. 2009;27(6):904-910.
99. Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol. 2013;31(7):930-937.
938
haematologica | 2018; 103(6)